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Highlights
• This is the first global report of wellbeing in oncology professionals since the COVID-
19 pandemic
• In this survey of 1520 oncology professionals, 67% reported a change in professional 
duties since COVID-19
• 25% had risk of distress (poor wellbeing), 35% felt burnout, and 66% not able to 
perform their job compared to pre-COVID-19
• Wellbeing and job performance since COVID-19 (JP-CV) were correlated with country 
of practice COVID-19 crude mortality rate
• The main predictors of wellbeing, burnout and JP-CV were resilience and changes to 
work hours
• JP-CV has improved but risk of distress and burnout has increased over time
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ABSTRACT 
Background
The impact of the COVID-19 pandemic on wellbeing has the potential for serious negative 
consequences on work, home life and patient care. The ESMO Resilience Task Force 
collaboration set out to investigate wellbeing in oncology over time since COVID-19. 
Methods
Two online anonymous surveys were conducted (Survey I: April/May 2020; Survey II: 
July/August 2020). Statistical analyses were carried out to examine group differences, 
associations and predictors of key outcomes: (1) wellbeing/distress (expanded Wellbeing 
Index (eWBI – 9 items)); (2) burnout (1 item from eWBI); (3) job performance since COVID-19 
(JP-CV – 2 items).
Results
Responses from survey I (1520 participants from 101 countries) indicate that COVID-19 is 
impacting oncology professionals with 25% of participants indicated being at risk of distress 
(poor wellbeing, eWBI ≥4), 38% reported feeling burnout, and 66% were not able to perform 
their job compared to pre-COVID-19. Higher JP-CV was associated with better wellbeing and 
not feeling burnout (p<0.01). Differences were seen in wellbeing and JP-CV between 
countries (p<0.001) and were related to country COVID-19 crude mortality rate (p<0.05). 
Consistent predictors of wellbeing, burnout and JP-CV were psychological resilience and 
changes to work hours. In survey II, among 272 participants who completed both surveys, 
whilst JP-CV improved (34% vs 51%, p<0.001), eWBI scores ≥4 and burnout rates were 
significantly higher compared to survey I (22% vs 31%, p=0.01; and 35% vs 49%, p=0.001 
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respectively) suggesting wellbeing and burnout have worsened over a three-month period 
during the COVID-19 pandemic. 
Conclusion 
In the first and largest global survey series, COVID-19 is impacting wellbeing and job 
performance of oncology professionals. JP-CV has improved but risk of distress and burnout 
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INTRODUCTION
The wellbeing of oncology healthcare professionals is fundamental in ensuring that the best 
care is provided for cancer patients.(1) The component of physician wellbeing most 
comprehensively studied is burnout.(1) The prevalence of burnout in oncologists is already 
known to be significant,(1, 2) and with the current unprecedented impact of COVID-19 on 
healthcare systems globally, the wellbeing of oncologists is likely to be affected. However, the 
true long-term nature and extent of this is unknown.   
In the early phase of COVID-19, oncology physicians in the United States and Singapore 
reported high levels of anxiety.(3, 4) In fact, the distress caused by COVID-19 is also 
experienced by physicians and surgeons across various specialties globally.(5-10) Increased 
burnout have been reported in frontline healthcare professionals surveyed globally through 
social media.(11) In the study from Wuhan, oncology physicians and nurses dispatched to 
work as frontline healthcare workers in a dedicated COVID-19 ward paradoxically had lower 
rates of burnout compared with colleagues who continued to work in their usual 
surroundings.(12) The authors hypothesised that direct involvement in combating COVID-19 
may have provided frontline healthcare workers with a greater sense of control and hence 
reduced burnout.(12) These findings highlight the complexity and diversity of the impact of 
COVID-19 on wellbeing across different global regions and specialties. 
The European Society for Medical Oncology (ESMO) established the ESMO Resilience 
Taskforce in December 2019 with a mandate to support wellbeing of oncology professionals 
after a high prevalence of burnout in young (≤40 years old) oncologists was previously 
identified.(2) Occupational factors integral to cancer care placing oncology professionals at 
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risk of burnout include delivering bad news, discussing and supervising complex treatment 
decisions with risk of toxicities and often without substantial prolongation of survival, 
pressures to keep at the forefront of scientific advances, and deliver research at a time where 
resources are challenged.(2) Substance abuse,(11) depression, suicide,(13, 14) medical 
errors,(12) professional misconduct,(15) and leaving oncology and early retirement(14, 16) 
have all been linked with burnout or poor wellbeing. These potential consequences could 
have a serious negative impact on patient care.(2) 
In response to the COVID-19 pandemic, the ESMO Resilience Task Force launched a series of 
global surveys to evaluate the impact of challenges posed by COVID-19 on daily practice, 
wellbeing, current levels of support, and coping strategies of oncologists and other oncology 
professionals globally in order to develop support strategies. The longitudinal nature of these 
surveys is designed to identify relevant issues as the pandemic evolves as well as the longer-
term impact on oncology professionals across countries.
Here, we report the findings of our first survey (Survey I) in this global series launched in 
April/May 2020, and also the initial results of a subgroup of participants who completed 
Survey II conducted in July/August 2020.  
METHODS
Survey design
The ESMO Resilience Task Force, in collaboration with ESMO Young Oncologists 
Committee, ESMO Women for Oncology Committee, ESMO Leaders Generation Programme 
Alumni members, and the OncoAlert Network, designed a series of online global surveys 
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launched at different time-points during the course of the COVID-19 pandemic. The project 
was approved by the ESMO Executive Board. The surveys, hosted on the Qualtrics platform, 
were available on the ESMO website, ESMO membership emails, and were promoted through 
social media. Participation was voluntary and anonymous. Participants who consented to 
longitudinal evaluation of their responses at different time-points were assigned a trackable 
unique identifier code. Survey I was available online from 16 April to 3 May 2020, and Survey 
II was launched three months following Survey I (16 July to 5 August). 
Survey measures
Sociodemographic, background variables, and three key outcomes of interest (wellbeing, 
burnout and job performance since COVID-19 (JP-CV)) were collected in the surveys (Table 
S1). In addition, psychological resilience, coping strategies, COVID-19-related job changes, 
perceptions of value and support, working environment, and changes to lifestyle were 
measured. 
Resilience to changes at work was measured using a single item bipolar measure using a 9-
point scale (low to high resilience).(17) Wellbeing was measured using the validated 
expanded Wellbeing Index (eWBI) screening tool consisting of 9 items.(15, 16, 18) Score of ≥4 
has been shown to be associated with distress, fatigue, burnout and low quality of life in 
clinician populations.(15) A single item from eWBI,(16) ‘have you felt burned out from your 
work?’ (‘yes’ or ‘no’), was used in this report as a surrogate question and preliminary screen 
of the current level of burnout amongst participants. JP-CV was measured by the mean score 
of two 5-point Likert scale (strongly disagree to strongly agree; scores 1 to 5) questions: 
‘compared to pre-COVID-19 outbreak, I am still able to do my job to the same standard’ and 
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‘I currently feel able to deliver the same standard of care to my patients as before the COVID-
19 outbreak’. JP-CV score of ≥3.5 was considered favourable JP-CV. 
Estimated crude mortality rate was calculated as a marker of the relative severity of COVID-
19 outbreak in each country. This was calculated based on total number of COVID-19-related 
deaths per million population in each respective country using publicly available data 
provided by the World Health Organization (WHO)(19) and worldometer(20) (Figure 1).
Statistical analysis
Descriptive data were presented as median (interquartile range, IQR) or mean±standard 
deviation (SD), and proportions were expressed as a percentage. Chi-square analysis was 
used to compare categorical variables and paired or unpaired t-test were used to analyse 
continuous variables. p-values were two-tailed. Bivariate correlations were used to examine 
association between crude mortality rate and outcome measures. Linear regression analyses 
were used to assess predictors of wellbeing and JP-CV, and binary logistic regression analyses 
were used to identify factors associated with burnout. Hierarchical regression analyses were 
used to control for mortality rate where appropriate. Otherwise univariate regression was 
conducted followed by multiple regression to identify predictive factors on the outcomes of 
interest. All statistical analyses were performed using SPSS V.25.0/26.0 a d data represented 
using GraphPad Prism V8.0.
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RESULTS
Demographic and baseline characteristics of participants
A total of 1520 participants from 101 countries, of which 1020 (67%) were from Europe, 
completed survey I in April/May 2020 (Table 1 and Table S2). Overall, there were 777 (51%) 
female participants, 833 (55%) participants over the age of 40 years, and a majority (n=1070, 
71%) were of white ethnicity. A total of 245 participants (16%) disclosed an increased 
personal risk due to underlying comorbidities or condition (Table S2). The most common 
primary place of work was general hospital (n=723, 48%) followed by cancer centre 
exclusively treating cancer patients (n=619, 41%). Almost all participants were clinicians, with 
medical oncologists most represented (n=1059, 70%). Trainees contributed to 22% (n=333) 
of responses, with majority having been in training for two or more years (n=262, 79%). More 
than half of non-trainees (n=688/1187, 58%) had more than 10 years of oncology experience. 
Majority of participants (n=1365, 90%) were ESMO members. 
Changes in professional duties and job performance since COVID-19
More than two-thirds (n=1024, 67%) of participants report d a change in their professional 
duties since the COVID-19 outbreak (Table 2). Almost half of respondents (n=744, 49%) were 
performing remote consultations, and a third (n=499, 33%) reported more hours working 
from home. Of note, 14% (n=206) were involved in COVID-19 inpatient work and 16% (n=237) 
in COVID-19-related research. There were a significant number of participants who reported 
reduced clinical trial activity (n=573, 38%) and other research activity in general (n=443, 29%). 
Few (n=87, 6%) were fully redeployed during the COVID-19 pandemic.
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In general, 49% (n=739) of participants reported that they were unable to do their job to the 
same standard compared to pre-COVID-19 and 53% (n=804) did not feel able to deliver the 
same standard of patient care (Figure 2C). Taken altogether, 66% (n=997) reported a mean 
JP-CV score of less than 3.5. Of note, 78% (n=1190) reported that their concerns for personal 
safety at work has increased due to COVID-19 (Figure S1). At the time of the survey, 19% 
(n=283) did not feel confident in being able to access COVID-19 testing if required, and 28% 
(n=418) did not have adequate access to personal protective equipment (PPE) at their 
workplace (Figure S1). Importantly, 62% (n=945) did have pleasant physical working 
conditions, 56% (n=857) had adequate control over most aspects of their job, and more than 
two-thirds (69%, n=1041) received adequate communication to do their job (Figure S1).
Wellbeing and burnout 
On the whole, there were 386 participants (25%) with a self-reported cumulative eWBI score 
of ≥4 (Figure 2A). The proportion of participants at risk of distress, with eWBI score of ≥4, 
were significantly higher among female (29% vs 22%, p=0.0017) and young oncology 
professionals (aged ≤40 years) (33% vs 19%, p<0.001). A total of 572 participants (38%) 
specifically answered ‘yes’ to the burnout question, and this was also higher among female 
(42% vs 34%, p=0.001) and young oncology professionals (43% vs 32%, p<0.001).
Outcome measures were analysed to determine the associations between them using 
standard Pearson (r) and point biserial (rpb) correlations. Higher job performance since COVID 
(JP-CV) was significantly associated with better wellbeing (r(1519)=-0·211, p<0.01) and not 
feeling burnout (rpb(1519)=-0.148, p=0.01). Feeling burnout was significantly associated with 
poorer wellbeing (rpb(1519)=0.672, p=0.01).
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Wellbeing support and coping strategies 
At the time of Survey I, wellbeing support services were accessible to 777 (51%) participants. 
Of these, 447 (58%) participants used a combination of approaches; most popular were online 
or smartphone apps, psychological support from work, and telephone support (Table S3). In 
addition, a variety of coping strategies were also used by participants including thinking of 
positives (n=740, 49%), a change in physical activity (n=726, 48%), talking to colleagues to get 
information (n=716, 47%), and using humour or laughing (n=623, 41%) (Table S3).
The majority of participants felt well-supported by their friends and/or family (n=1389, 91%), 
and colleagues (n=1254, 83%) (Table S3). More than half felt well-supported by the 
management at their workplace (n=864, 57%) and by global or national societies (n=864, 57%) 
(Table S3). Only 39% (n=585) reported feeling well-supported by their government. During 
this time, 75% (n=1142) felt valued by the public and 60% (n=908) felt valued by their work 
organisation.
Predictors of wellbeing, burnout and job performance since COVID-19
Correlational analyses were conducted on participants who stated their country of practice 
(n=1519) to explore if there was an association between the estimated COVID-19 crude 
mortality rate and key study measures in Survey I. There was a statistically significant 
relationship between crude mortality rate and wellbeing (r(1519)=0.061, p<0.05) and JP-CV 
(r(1519)=-0.115, p<0.01); as the crude mortality rate increases, there is poorer wellbeing and 
JP-CV. This was controlled for in the following regression analyses. Feeling burnout varied 
between countries but was not associated with COVID-19 crude mortality rate (p>0.05). 
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Regression analyses showed lower levels of distress was significantly (p<0.05) associated with 
age above 40 years, male gender, having pleasant working conditions, feeling valued by their 
organisation, a change in physical activity, having higher levels of psychological resilience, no 
increase in working hours, no reduction in their clinical trial activity, having no concern about 
the impact of COVID-19 on their training and career, no experience of self-isolation due to 
COVID-19 symptoms, not feeling worried about personal wellbeing, no changes in diet, not 
‘talking to colleagues for emotional support’, and choosing not to ‘avoid thinking about 
things’ (Figure 3A).
Higher JP-CV scores were significantly (p<0.05) predicted by white ethnicity, by specialists in 
surgical oncology or haematology, having adequate job control, higher level of psychological 
resilience, having no reduction in their clinical trial activity, not working more hours from 
home, not worried COVID-19 will have a negative impact on cancer research in their 
institution, and not using ‘distraction’ as a coping strategy (Figure 3B). 
Burnout was significantly (p<0.05) associated with having more out-of-hours work, increased 
number of working hours, concern about the impact of COVID-19 on training or career, feeling 
worried about wellbeing, and access to psychiatrist or psychologist, those from white 
ethnicity, those who reported working in unpleasant working conditions, feel unsupported by 
their government, and had lower levels of psychological resilience (Figure 3C). 
Subgroup analysis of participants who completed both surveys I and II
In survey II (July/August 2020), there were 272 participants from survey I who agreed to 
longitudinal follow-up of their responses to both surveys. Compared to survey I, there was a 
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significant increase in the proportion of participants at risk of distress (eWBI score of ≥4) (31% 
vs 22%, p=0.0115) (Figure 4A) and self-reporting burnout (49% vs 35%, p=0.0013) (Figure 4B). 
The proportion of participants reporting favourable job performance since COVID-19 (JP-CV) 
(mean score ≥3.5) increased from 38% to 54% (p=0.0005) (Figure 4C).
DISCUSSION 
The importance of wellbeing and burnout, and their impact on delivering healthcare has 
increasingly been recognised over the years. The COVID-19 pandemic poses additional, 
extreme challenges on healthcare systems worldwide and health care professionals have to 
maintain patient care whilst facing personal risks. However, reports on the immediate and 
long-term effects of such a crisis on healthcare professionals are limited. In a survey of Italian 
doctors (hospital, primary care and freelance) during the first lockdown period (March 2020), 
wellbeing (using WHO-5 Well-Being Index) was rated poor by 59%.(21) The authors noted the 
need for follow-up surveys to monitor wellbeing and distress.(21) The ESMO Resilience Task 
Force survey collaboration provides the largest and most comprehensive report on the 
current wellbeing of oncology professionals in response to the COVID-19 pandemic across the 
world. 
Survey I revealed that oncologists working in different countries varied in terms of their 
perceived wellbeing and job performance since COVID-19 (JP-CV), and there appeared to be 
worse self-reported wellbeing and JP-CV in countries with a higher COVID-19 crude mortality 
rate. A similar finding was reported amongst Spanish healthcare workers, where there were 
higher distress levels in areas with the highest incidence of COVID-19.(22) Encapsulating the 
dynamic changes of COVID-19 globally for comparison is challenging particularly because of 
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discordant methodology for cases and deaths between countries. We felt the estimated 
COVID-19 crude mortality rate was a measure that could represent the situation most 
reproducibly and accurately at the time.  However, most countries have experienced regional 
variation of mortality rate.
In this survey series, the expanded wellbeing index (eWBI) was selected to measure wellbeing. 
The self-reported eWBI, developed initially at Mayo Clinic,(15, 16, 18) measures six 
dimensions of distress and wellbeing. It is a validated screening tool used to measure 
wellbeing over time in large cohorts of US clinicians and non-clinicians.(15, 16, 18) To our 
knowledge, this is the first large survey to report on the utilisation of the eWBI in a global 
setting. 
There are multiple methods of assessing burnout in literature.(1) The Maslach Burnout 
Inventory (MBI) is the most extensively used.(23) Whilst historically considered the gold 
standard, it is recognised that other instruments that are brief and have the ability to screen 
for multiple dimensions of distress, may be more practical for healthcare professionals to 
complete in busy working environments. In this survey series, we have used participant 
answers to the specific burnout question from the eWBI as a readout for prevalence of feeling 
burnout at a time point. Our intention was to establish how participants consider themselves 
feeling burnout which can be easily assessed over time. The rates of self-reported ‘feeling 
burnout’ described in this survey series, is in keeping with burnout rates reported in earlier 
studies that used different, validated methods to assess burnout in oncologists (34-70%).(2, 
24-26) 
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We found consistently that, among others, working hours and participants’ psychological 
resilience were significant factors associated to overall better wellbeing, level of burnout and 
JP-CV. Other notable findings were that the risk of distress and burnout appeared to be 
significantly higher in female compared to male colleagues. Similarly, wellbeing and burnout 
rates were worse among young oncology professionals (≤40 years). There were also other 
critical findings related to clinical practice noted. A large majority (78%) of participants were 
concerned for their personal safety at work. More than a quarter of participants did not have 
adequate access to personal protective equipment (PPE), and 19% did not feel confident in 
being able to access COVID-19 testing if required. Over two-thirds of oncology professionals 
noted a change in professional duties with more hours working from home and increased use 
of remote consultations being common reasons. These findings reflect the fact that COVID-
19 has forced the rapid adoption and optimisation of telemedicine as an alternative mode 
maintaining the delivery of patient care whilst reducing footfall.(27) 
Our survey series has shed light on various wellbeing support and coping strategies used by 
survey participants in response to the circumstantial changes imposed by COVID-19. 
However, only slightly more than half of the participants reported having access to wellbeing 
support services. This raises some concern about the equitable provision and/or awareness 
of support to the oncology profession. A supportive institutional programme was noted as a 
significant factor affecting both anxiety and depressive symptom levels during COVID-19 in a 
survey of researchers in the field of radiation oncology (28).  In addition, the authors reported 
the feeling of a little or a lot of guilt being more abundant when self-perceived productivity 
declined. 
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Although the ESMO Resilience Taskforce first survey had over 1500 participants representing 
more than 100 countries globally, it has the inherent limitations by virtue of primarily being a 
membership survey with 90% of participants being ESMO members. It is not possible to 
establish the proportion of oncology professionals who participated in the survey globally.  
The number of participants varied across countries with the majority from Europe (highest 
participation from: United Kingdom (n=174), Italy (n=124), Spain (n=102), Germany (n=84) 
and India (n=82)). Most participants were doctors with 70% medical oncologists. Importantly, 
22% of survey I participants were trainees which is in keeping with the current proportion of 
trainee doctors within the ESMO membership (23%). There were representative proportions 
for age (45% ≤40 years) and gender (51% male, 49% female). Important considerations for 
the survey design was balancing the time to complete the survey, complexity of questions in 
an international setting where English may not be the first language of participants, and key 
information of interest for oncology professionals and organisations. This meant that brief, 
concise, tools assessing key outcomes of interest were selected in order to minimise the 
burden of completing these surveys during these unprecedented COVID-19 times. 
Our findings are based on self-reported experiences of oncology healthcare professionals 
who were aware of the surveys and decided to participate. Therefore, there is a potential for 
bias. Nevertheless, this survey provides a snapshot of the acute reaction of oncology 
professionals to COVID-19 across different countries. We believe that the observations made 
here will be dynamic as the pandemic evolves, and further strengthened by the ongoing 
longitudinal analyses, which will be reported and obtained in subsequent surveys. 
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The key strength of this survey series is the ability to analyse important outcomes of interest 
over time.  In this report, we presented wellbeing at two time points three months apart and 
observed that in this longitudinal cohort of participants, poor wellbeing and feeling burnout 
has increased. However, job performance improved and may be a reflection of the increase 
in knowledge, education and experience managing cancer patients in the COVID-19 era. 
Although the improved self-perceived JP-CV noted is reassuring for patient care, this will be 
continually assessed as part of subsequent surveys, together with the long-term impact on 
wellbeing and burnout, in order to evaluate if job performance is maintained.
Supporting wellbeing and minimising the risk of burnout are priorities in order to ensure 
patient management pathways and cancer care are not additionally compromised as a result 
of COVID-19. The results of the ESMO Resilience Taskforce surveys will contribute to raising 
awareness and developing support solutions for individuals, hospital organisations and 
societies. Measures such as taking action on factors associated with more favourable 
outcomes in this survey including tackling issues in relation to working hours, addressing 
concerns with regards to the impact of COVID-19 on training or career and clinical trials, and 
improving staff resilience to change are essential. 
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TABLE CAPTIONS
Table 1 Participant demographics (n=1520).
Table 2 Change in professional duties since the COVID-19 outbreak (n=1520).
FIGURE CAPTIONS
Figure 1 Estimated crude mortality rate due to COVID-19 in countries where 
participants are working in (n=1520 from 101 countries) during the survey 
period (16 April to 3 May 2020). 
Figure 2 (A) Self-reported wellbeing, (B) resilience, and (C) job performance since 
COVID-19 (JP-CV) during the COVID-19 crisis (n=1520). 
Figure 3 Hierarchical multiple regression and multiple logistic regression analyses of 
predictive variables associated with (A) self-reported wellbeing (n=1518) and 
(B) job performance since COVID-19 (JP-CV) (n=1494), and (C) burnout 
(n=1494), respectively. Note: adichotomous variable (0= no, 1= yes; 0= ≤40 
years, 1= >40 years; or 0 = white; 1 = non-white); bLikert scale (1= strongly 
disagree – 5= strongly agree); cLikert scale (1= not at all – 5= extremely); 
dbipolar scale (1 = reflects low resilience – 9 = reflects high resilience).
Figure 4 Paired longitudinal comparison between survey I (April/May 2020) and survey 
II (July/August 2020) of key measures: (A) self-reported wellbeing, (B) burnout, 































































Confidential: For Review Only
Banerjee et al. 24
and (C) job performance since COVID-19 (JP-CV), during the COVID-19 crisis 
among those who completed both surveys (n=272). (*p<0.05, **p<0.01, 
***p<0.001).
SUPPLEMENTARY DATA
Table S1 Outcome measures of interest.
Table S2 Personal and lifestyle issues of relevance to the COVID-19 pandemic (n=1520).
Table S3 Wellbeing support and coping strategies amongst participants during the 
COVID-19 crisis (n=1520).
Figure S1 Working environment during the COVID-19 crisis (n=1520).
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Table 1
Number, n (%)













Prefer not to say 21 (1%)
Europe* 1020 (67%)
   Southwestern Europe 271 (18%)
   Central Europe 248 (16%)
   Northern Europe and British Isles 247 (16%)
   Western Europe 109 (7%)
   Southeastern Europe 103 (7%)
   Eastern Europe 42 (3%)
Asia 261 (17%)
North America 79 (5%)




Prefer not to say 1 (0.1%)
General hospital 723 (48%)
Cancer centre 619 (41%)
Private outpatient clinic 65 (4%)
Pharmaceutical/technology company 36 (2%)
Healthcare organisation 18 (1%)
Primary place of work
Other 59 (4%)
Medical oncology 1059 (70%)
Clinical oncology 271 (18%)
Haemato-oncology 123 (8%)
Radiation oncology 88 (6%)
Palliative care 86 (6%)
Laboratory-based researcher/scientist 53 (4%)
















Not applicable 10 (1%)
Yes 1365 (90%)ESMO member
No 155 (10%)
*Southwestern Europe – Italy, Portugal, Spain; Central Europe – Austria, Czech Republic, Germany, Hungary, Poland, Romania, Slovakia, 
Slovenia, Switzerland; Northern Europe and the British Isles – Denmark, Finland, Norway, Republic of Ireland, Sweden, United Kingdom; 
Western Europe – Belgium, France, Luxembourg, The Netherlands; Southeastern Europe – Albania, Bosnia and Herzegovina, Bulgaria, 
Croatia, Cyprus, Greece, Israel, Kosovo, Montenegro, North Macedonia, Serbia, Turkey; and Eastern Europe – Belarus, Estonia, Georgia, 
Latvia, Lithuania, Moldova, Russian Federation, Ukraine).
†Note that some participants have selected 2 or more specialties within their job role, and proportion of representation is summarised as such.
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Table 2
Number, n (%)
Yes 1024 (67%)Change in professional 
duties No 496 (33%)
Scope of clinical work
   More remote (video/telephone) consultations 744 (49%)
   Increased direct patient care 103 (7%)
   Less inpatient work 388 (26%)
   More inpatient work 148 (10%)
   COVID-19 inpatient work 206 (14%)
   Cover other oncology non-COVID-19 patients 187 (12%)
   Cover non-oncology specialties 168 (11%)
Working hours and shift patterns
   More hours working from home 499 (33%)
   Reduced number of hours of work 373 (25%)
   Increased number of hours of work 254 (17%)
   More out of hours work in hospital 242 (16%)
   More weekend shifts 175 (12%)
   More overnight shifts 122 (8%)
Clinical trial and research
   Reduced clinical trial activity 573 (38%)
   Reduced research (non-clinical trials) activity 443 (29%)
Nature of change in 
professional duties





Yes 154 (43%)Redeployment relevant 
to prior training, n=362 No 208 (57%)
Yes 114 (55%)Adequate training for 
redeployment, n=208 No 94 (45%)
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Figure 1 | Estimated crude mortality rate due to COVID-19 in countries where participants are working in 
(n=1520 from 101 countries) during the survey period (16 April to 3 May 2020). 
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Figure 2 | (A) Self-reported wellbeing, (B) resilience, and (C) job performance since COVID-19 (JP-CV) 
during the COVID-19 crisis (n=1520). 
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Figure 3 | Hierarchical multiple regression and multiple logistic regression analyses of predictive variables 
associated with (A) self-reported wellbeing (n=1518) and (B) job performance since COVID-19 (JP-CV) 
(n=1494), and (C) burnout (n=1494), respectively. Note: adichotomous variable (0= no, 1= yes; 0= ≤40 
years, 1= >40 years; or 0 = white; 1 = non-white); bLikert scale (1= strongly disagree – 5= strongly 
agree); cLikert scale (1= not at all – 5= extremely); dbipolar scale (1 = reflects low resilience – 9 = reflects 
high resilience). 
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Figure 4 | Paired longitudinal comparison between survey I (April/May 2020) and survey II (July/August 
2020) of key measures: (A) self-reported wellbeing, (B) burnout, and (C) job performance since COVID-19 
(JP-CV), during the COVID-19 crisis among those who completed both surveys (n=272). (*p<0.05, 
**p<0.01, ***p<0.001). 
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Supplementary Table S1
Outcome measures of interest.
Items Response options
Since the COVID-19 outbreak:
1. Have you felt burned out from your work? Binary response; no [0], yes [1]
2. Have you worried that your work is hardening you 
emotionally?
Binary response; no [0], yes [1]
3. Have you often been bothered by feeling down, 
depressed or hopeless?
Binary response; no [0], yes [1]
4. Have you fallen asleep while sitting inactive in a 
public space?
Binary response; no [0], yes [1]
5. Have you felt that all things you had to do were piling 
up so high that you could not overcome them?
Binary response; no [0], yes [1]
6. Have you been bothered by emotional problems (such 
as feeling anxious, depressed or irritable)?
Binary response; no [0], yes [1]
7. Has your physical health interfered with your ability 
to do your daily work at home and/or away from 
home?
Binary response; no [0], yes [1]
“The work I do is meaningful to me” 7-point Likert scale; very 




“My work schedule leaves me enough time for my 
personal/family life”
5-point Likert scale; strongly 
disagree [1] to strongly agree [5]
‘Compared to pre-COVID-19 outbreak, I am still able to do my 
job to the same standard’
5-point Likert scale; strongly 





composite created of 
the two items
‘I currently feel able to deliver the same standard of care to my 
patients as before the COVID-19 outbreak’
5-point Likert scale; strongly 
disagree [1] to strongly agree [5]
Burnout Have you felt burned out from your work? Binary response; no [0], yes [1]
*Kuder-Richardson 20 for the WBI-7 was 0.766.
†Chronbach’s Alpha for the JP-CV was 0.736.
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Supplementary Table S2




Increased personal risk due 
to comorbidities or condition
Prefer not to say 40 (3%)
Respiratory 78 (5%)
Cardiac 77 (5%)
Diabetes mellitus 30 (2%)
Immunosuppressed 26 (2%)











Prefer not to say 2 (0.1%)
Yes 
   <2 weeks 117 (8%)
   2-4 weeks 66 (4%)
   >4 weeks 41 (3%)




   <2 weeks 121 (8%)
   2-4 weeks 66 (4%)
   >4 weeks 20 (1%)
Needed to self-isolate due to 
contact with known COVID-
19 positive individuals
No 1313 (86%)
Yes 359 (24%)Tested for COVID-19
No 1161 (76%)
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Supplementary Table S3
Wellbeing support and coping strategies used by participants during the COVID-19 crisis (n=1520).
Number, n (%)
Access to wellbeing 
support services
Yes 777 (51%)
Online or smartphone apps 236 (16%)
Psychological support from work 161 (11%)
Telephone support 140 (9%)
Spiritual or religious support 123 (8%)
Personal psychiatrist/psychologist 60 (4%)
Psychological support from national organisations 29 (2%)





By friends and/or family 1389 (91%)
By colleagues at workplace 1254 (83%)
By management of workplace 864 (57%)
By global or national societies 864 (57%)
Feeling well-supported 
during COVID-19
By government 585 (39%)
By the public 1142 (75%)Feeling valued
By work organisation 908 (60%)
Thinking of positives 740 (49%)
Change in physical activity (e.g. exercise) 726 (48%)
Talking to colleagues to get information 716 (47%)
Using humour, laughing 623 (41%)
Distracting myself 505 (33%)
Talking to colleagues to get emotional support 484 (32%)
Strategising and planning steps to take 440 (29%)
Changes in diet (e.g. types of food, amount) 409 (27%)
Avoiding thinking about or not thinking about it 306 (20%)
Using meditation, mindfulness or other relaxation techniques 282 (19%)
Using religious or spiritual practice(s) 277 (18%)
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